Sufentanil for chronic pain management

Future Neurology

Volumn 5, Issue 6, 2010, Pages 791-796

  Joshi, Girish P ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cancer pain; chronic pain; noncancer pain; opioids; sufentanil

Indexed keywords

BUPIVACAINE; FENTANYL; MORPHINE; NARCOTIC ANALGESIC AGENT; SUFENTANIL;

ARTICLE; BRADYCARDIA; BREATHING RATE; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; ENDOCRINE DISEASE; EUPHORIA; GRANULOMA; HUMAN; HYPERALGESIA; HYPERCAPNIA; HYPOTENSION; HYPOXEMIA; IMMUNITY; LIPID SOLUBILITY; NAUSEA; PHARMACODYNAMICS; POSTMARKETING SURVEILLANCE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SLEEP DISORDER; UPPER RESPIRATORY TRACT OBSTRUCTION; URINE RETENTION; VOMITING;

EID: 78650266258     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.10.67     Document Type: Article

References (27)

1. Chapman CR, Lipschitz DL, Angst MS et al.: Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J. Pain 11(9), 807-829 (2010).
2. Ballantyne JC, Mao J: Opioid therapy for chronic pain. N. Engl. J. Med. 349, 1943-1953 (2003).
3. Noble M, Treadwell JR, Tregear SJ et al.: Long-term opioid management for chronic noncancer pain. Cochrane Database Syst. Rev. 1, CD006605 (2010).
4. Pergolizzi J, Boger Budd K et al.: Opioids and management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 8, 287-313 (2008).
5. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10, 113-130 (2009).
6. Trescot AM, Helm S, Hansen H et al.: Opioids in the management of chronic non-cancer pain: an update of American society of the interventional pain physician's (ASIPP) guidelines. Pain Physician 11, S5-S62 (2008).
7. Portenoy RK, Bennett DS, Rauck R et al.: Prevalence and characteristics of breakthrough pain in opioid treated patients with chronic noncancer pain. J. Pain 7, 583-591 (2006).
8. Davis MP: Recent development in therapeutics for breakthrough pain. Expert Rev. Neurother. 10, 757-773 (2010).
9. Fine PG, Portenoy RK: Establishing 'best practices' for opioid rotation: conclusions of an expert panel. J. Pain Symptom Manage. 38, 418-425 (2009).
10. Knotkova H, Fine PG, Portenoy RK: Opioid rotation: the science and the limitations of the equianalgesic dose table. J. Pain Symptom Manage. 38, 426-439 (2009).
11. McCracken LM, Velleman SC, Eccleston C: Patterns of prescription and concern about opioid analgesics for chronic non-malignant pain in general practice. Prim. Health Care Res. Dev. 9, 146-156 (2008).
12. Monk JP, Beresford R, Ward A: Sufentanil: a review of its pharmacological properties and therapeutic uses. Drugs 36, 286-313 (1988).
13. Lavrijsen K, van Houdt J, van Dyck D et al.: Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans. Drug Metab. Dispos. 18, 704-710 (1990).
14. Smith HS: Opioid metabolism. Mayo Clin. Proc. 84, 613-624 (2009).
15. Fisher DM, Kellett N, Lenhardt R: Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. Anesthesiology 99, 929-937 (2003).
16. Simpson DM, Messina J, Xie F, Hale M: Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 29, 588-601 (2007). (Pubitemid 47016640)
17. Good P, Jackson K, Brumley D, Ashby M: Intranasal sufentanil for cancer-associated breakthrough pain. Palliat. Med. 23, 54-58 (2009).
18. Minkowitz HS, Yarmush J, Donnell MT, Tonner PH, Damaraju CV, Skowronski RJ: Safety and tolerability of fentanyl iontophoretic transdermal system: fndings from a pooled data ana lysis of four clinical trials. J. Opioid Manag. 6, 203-210 (2010).
19. Tassinari D, Sartori S, Tamburini E et al.: Transdermal fentanyl as a front-line approach to moderate-severe pain: a meta-ana lysis of randomized clinical trials. J. Palliat. Care 25, 172-180 (2009).
20. Paix A, Coleman A, Lees J et al.: Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 63, 263-269 (1995).
21. Joshi GP: Chronogesic (durect). IDrugs 6, 368-371 (2003).
22. Waara-Wolleat KL, Hildebrand KR, Stewart GR: A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med. 7, 251-256 (2006).
23. Hassenbusch SJ, Portenoy RK: Current practices in intraspinal therapy-a survey of clinical trends and decision making. J. Pain Symptom Manage. 20, S4-S11 (2000).
24. Ahmed SU, Martin NM, Chang Y: Patient selection and trial methods for intraspinal drug delivery for chronic pain: a national survey. Neuromodulation 8, 112-120 (2005).
25. Hassenbusch SJ, Stanton-Hicks MD, Soukup J, Covington E, Boland MB: Sufentanil citrate and morphine/bupivacaine as alternative agents in chronic epidural infusions for intractable non-cancer pain. Neurosurgery 29, 76-82 (1991).
26. Harris JD: Management of expected and unexpected opioid-related side effects. Clin. J. Pain 24, S8-S13 (2008).
27. Bjørn AM, Jepsen P, Larsson HJ et al.: Hospitalizations for opioid poisoning: a nation-wide population-based study in Denmark, 1998-2004. Addiction 104, 104-108 (2009).